Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Aeolus Pharmaceuticals, Inc.
Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient with ALS
October 17th, 2008
Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) announced that it has initiated a follow-on Phase I open label compassionate use multiple dose study of AEOL 10150 in a patient diagnosed with progressive and debilitating amyotrophic lateral sclerosis, also referred to as ALS or Lou Gehrig's disease. The study is being conducted at UCLA by Martina Wiedau-Pazos, M.D., and is designed to evaluate the safety and efficacy of AEOL 10150 in an ALS patient over an extended period of time. The patient will receive a subcutaneous injection of 75mg of AEOL 10150 two times each day for up to 24 weeks. Efficacy and safety data will be monitored in real-time for the duration of the study. The primary...
Source: Health Business Week (2008-10-17)
|
|
Advertisement |
|
|
|
